HomeProductsBuilding BlocksHeterocyclic ScaffoldsPurinesRoscovitine
Chemical structure of CAS 186692-46-6

Roscovitine

In Stock•Starting at $21 for 1 mg•Purity ≥ 98%
CAS No.186692-46-6
MDL No.MFCD02266401
MFC19H26N6O
MW354.40
InChI KeyBTIHMVBBUGXLCJ-OAHLLOKOSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$21In Stock
5 mg98%$44In Stock
10 mg98%$77In Stock
25 mg98%$161In Stock
50 mg98%$184In Stock
100 mg98%$278In Stock
250 mg98%$692In Stock
1 g98%$1454In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Seliciclib is 2,6-diaminopurine with benzylamino, (2R)-1-hydroxybutan-2-yl, and isopropyl substituents at C-6, C-2-N, and N-9, respectively. It is an experimental CDK inhibitor and antiviral drug.

CAS No.186692-46-6
Product NameRoscovitine

Biological Targets

CDK1·CDK2·CDK5·CDK7·CDK9

Associated Conditions

cystic fibrosis·breast cancer·non-small cell lung carcinoma·neoplasm·pituitary-dependent Cushing's disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Blood • Vol. 106, Issue 3 • 2005
PMID: 15827128PMC: PMC1895150DOI: 10.1182/blood-2005-01-0320

Antiviral activity of CYC202 in HIV-1-infected cells.

The Journal of biological chemistry • Vol. 280, Issue 4 • 2005
PMID: 15531588DOI: 10.1074/jbc.M406435200

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

Molecular cancer therapeutics • Vol. 4, Issue 1 • 2005
PMID: 15657360

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

Expert opinion on investigational drugs • Vol. 14, Issue 4 • 2005
PMID: 15882121DOI: 10.1517/13543784.14.4.457

Documentation

Similar Products